Prathana Prakash, MD
Neurology · Providence, RINPI 1942683719
Payments from drug & device makers
What this record shows
This record is dominated by grants: $29,458 of the $31,048 with a category attached, or 94.9%. Boston Scientific accounts for 62.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $14,061 and has fallen 98.8% since, to $164 in 2025.
Across 22 payments — averaging $1411.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$19K
- Medtronic$11K
- Teva Pharmaceuticals USA, Inc.$133
- Lundbeck LLC$65
- Genentech USA, Inc.$11
What the payments were for
- Grants$29,45895%
- Travel & lodging$6962%
- Food & beverage$8943%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 16 | $19,342 |
| Medtronic(2 entities) | 3 | $11,498 |
| Teva Pharmaceuticals USA, Inc. | 1 | $133 |
| Lundbeck LLC | 1 | $65 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERCISE$18,684
- ACTIVA$11,458
- GENERAL DBS$164
- AUSTEDO$133
How this compares
$31,048 in reported general payments places this provider in the 85th percentile of 86 neurology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 24 | $200,589 |
| RytaryCarbidopa/Levodopa | 63 | $66,186 |
| MyrbetriqMirabegron | 46 | $25,060 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 508 | $18,546 |
| NeuproRotigotine | 12 | $11,782 |
| Carbidopa | 30 | $10,940 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 149 | $7,212 |
| AmantadineAmantadine Hcl | 123 | $6,801 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 13 | $2,919 |
| Primidone | 81 | $2,547 |
| Rivastigmine | 12 | $1,414 |
| RivastigmineRivastigmine Tartrate | 17 | $1,299 |
| Propranolol Hcl | 55 | $1,138 |
| Ropinirole Hcl | 24 | $1,078 |
| Zolpidem Tartrate ErZolpidem Tartrate | 11 | $818 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $133 | $200,58924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 86 neurology providers in Rhode Island.
Other neurology in Providence
- Stephen SallowayProvidence$329K
- Syed RizviProvidence$160K
- John EastonProvidence$112K
- Saima ChaudhryProvidence$90K
- Monica DhakarProvidence$45K
- Jeffrey WishikProvidence$34K
- Karen FurieProvidence$29K
- Chuang WuProvidence$14K
- Emily WeisbachProvidence$11K
- Shawn TsekhanProvidence$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.